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Abstract
Intervention trials with supplemental -carotene have
observed either no effect or a harmful effect on lung
cancer risk. Because food composition databases for
specific carotenoids have only become available recently,
epidemiological evidence relating usual dietary levels of
these carotenoids with lung cancer risk is limited. We
analyzed the association between lung cancer risk and
intakes of specific carotenoids using the primary data
from seven cohort studies in North America and Europe.
Carotenoid intakes were estimated from dietary
questionnaires administered at baseline in each study. We
calculated study-specific multivariate relative risks (RRs)
and combined these using a random-effects model. The
multivariate models included smoking history and other
potential risk factors. During follow-up of up to 7–16
years across studies, 3,155 incident lung cancer cases
were diagnosed among 399,765 participants. -Carotene
intake was not associated with lung cancer risk (pooled
multivariate RR  0.98; 95% confidence interval, 0.87–
1.11; highest versus lowest quintile). The RRs for -
carotene, lutein/zeaxanthin, and lycopene were also close
to unity. -Cryptoxanthin intake was inversely associated
with lung cancer risk (RR  0.76; 95% confidence
interval, 0.67–0.86; highest versus lowest quintile). These
results did not change after adjustment for intakes of
vitamin C (with or without supplements), folate (with or
without supplements), and other carotenoids and
multivitamin use. The associations generally were similar
among never, past, or current smokers and by
histological type. Although smoking is the strongest risk
factor for lung cancer, greater intake of foods high in
-cryptoxanthin, such as citrus fruit, may modestly lower
the risk.
Introduction
Although cigarette smoking is the leading cause of lung cancer,
only 15% of smokers are eventually diagnosed with lung cancer
(1). This indicates that other factors, such as inherited differ-
ences (2), occupational or environmental exposures, or dietary
habits (1, 3), may influence the outcome of exposure to chem-
ical carcinogens in tobacco.
Carotenoids are red and yellow fat-soluble pigments found
in many fruits and vegetables. The major carotenoids with
vitamin A activity in human plasma are -carotene, -carotene,
and -cryptoxanthin, whereas the major carotenoids without
vitamin A activity are lycopene, lutein, and zeaxanthin (4).
Carrots contain high amounts of -carotene and -carotene.
Broccoli and spinach provide lutein and its isomers whereas
tomatoes contain high amounts of lycopene. -Cryptoxanthin is
mainly derived from orange juice, oranges, and tangerines
(4–7).
In intervention trials, pharmacological doses of -carotene
supplements provided no protection against lung cancer com-
pared with placebo (8–11). In fact, supplemental -carotene
modestly increased lung cancer risk in heavy smokers (8, 9) and
asbestos workers (8). Although -carotene at usual dietary
levels has been inversely associated with lung cancer risk in
some epidemiological studies, the current evidence is more
consistent for showing a benefit of high consumption of fruits
and vegetables (1, 12). Thus, -carotene may not be among the
nutrient(s) responsible for the inverse associations observed
between fruit and vegetable consumption and lung cancer but
rather may be an indicator of other bioactive components in
these foods. As detailed food composition databases for spe-
cific carotenoids have become available only recently (5, 7),
few studies have examined their associations with lung cancer
risk, and their results have been inconsistent (13–22).
To gain a better understanding of how intakes of specific
carotenoids (-carotene, -carotene, -cryptoxanthin, lutein/
zeaxanthin, and lycopene) are related to lung cancer risk, we
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analyzed the primary data from seven large cohort studies
carried out in North America and Europe. These studies, taken
together, provided a wide range of carotenoid intakes, a rela-
tively large number of cases, and allowed for separate analyses
by smoking status and by histological type of lung cancer.
Materials and Methods
The Pooling Project of Prospective Studies of Diet and Cancer
(the Pooling Project) has been described previously (23). For
the carotenoid and lung cancer analyses, we identified seven
cohort studies (Table 1; Refs. 17–20, 24, 25) that met the
following predefined criteria: at least 50 incident lung cancer
cases, assessment of long-term dietary intake including the
specific carotenoids, a validation study of the dietary question-
naire or of a closely related instrument, and assessment of
smoking status. The Adventist Health Study (26), the New
York University Women’s Health Study (27), and Sweden
Mammography Cohort (28), all included in the Pooling Project,
were thus excluded because they did not assess intakes of the
specific carotenoids (26), nor did they assess smoking status at
baseline (27, 28).
Outcome Ascertainment Lung cancer cases were ascertained
using follow-up questionnaires with subsequent medical record
review (17, 19) and/or linkage with a cancer registry (18–20,
24, 25). In addition, some studies used linkage with a death
registry or death certificates (17, 19, 20, 29). We categorized
lung cancers by histological type based on International Clas-
sification of Diseases for Oncology morphology codes (30) or
the histological classification provided by the original study
investigators.
Both the Netherlands Cohort Study and the New York
State Cohort Study included women and men; each study was
analyzed as two separate cohorts defined on the basis of sex. To
take advantage of the more extensive diet assessment com-
pleted in 1986, the cases and person-time accumulated in the
Nurses’ Health Study were divided into two groups for analysis
(1980–1986 and 1986–1996); these cohorts were referred to as
the Nurses Health Study (a) and the Nurses Health Study (b),
respectively.
Dietary Assessment Food consumption was assessed at base-
line using a validated dietary questionnaire developed for each
study population (31–37). The number of food items on the
questionnaires ranged from 45 (New York State Cohort) to 276
(-Tocopherol, -Carotene Cancer Prevention Study). The
food data were converted into daily nutrient intakes by the
software and food composition database of each cohort study
before they were sent to the Department of Nutrition at the
Harvard School of Public Health. Nutrients were energy-
adjusted according to the residual method (38) by using the
predicted intake at 2100 kcal/day in men and at 1600 kcal/day
in women. Mean energy intake ranged from 1988 kcal/day
(Health Professionals Follow-up Study) to 2804 kcal/day (-
Tocopherol, -Carotene Cancer Prevention Study) in men and
from 1569 kcal/day [Nurses’ Health Study (a)] to 2066 kcal/day
(Canadian National Breast Screening Study) in women. Lutein
intake was combined with zeaxanthin intake because of the
difficulty in separating these two carotenoids in laboratory
analyses (5, 7).
Few of the validation studies (31, 33–37, 39) for the
dietary assessment methods used in these cohorts (or of closely
related instruments) examined specific carotenoids. The corre-
lation coefficients between dietary intakes and plasma concen-
trations varied between 0.21 for lycopene and 0.48 for -
carotene in a sample of women who were nonsmokers in the
Nurses’ Health Study, and between 0.35 for -carotene and
0.47 for -carotene among a sample of men who were non-
smokers in the Health Professionals Follow-up Study (40). The
correlation coefficient between a food frequency questionnaire
similar to the one used in the Canadian National Breast Screen-
ing Study and a seven-day dietary record was 0.60 for -
carotene (37). -Cryptoxanthin is concentrated in fruits,
particularly citrus fruits and fruit juices (4, 7). Because -
cryptoxanthin intake is highly correlated with dietary vitamin C
intake (correlation coefficients ranged from 0.52 to 0.77 in
Table 1 Characteristics of the cohort studies included in the pooled analysis of dietary energy-adjusted carotenoids and lung cancer
Study Follow-up period Baseline
cohort size
Number of
cases
Mean (SD) g/day
-carotene -carotene -cryptoxanthin Lutein/Zeaxanthin Lycopene
-Tocopherol, -Carotene Cancer
Prevention Study
Men 1985–1996 6771a 298 527 (505) 1758 (1262) 25 (30) 1146 (328) 645 (597)
Canadian National Breast Screening Study
Women 1980–1993 56837 149 986 (818) 4619 (2939) 79 (58) 3037 (3096) 8891 (8933)
Health Professionals Follow-up Study
Men 1986–1996 44350 244 980 (1036) 5159 (3591) 88 (103) 3949 (3013) 10844 (7795)
Iowa Women’s Health Study
Women 1986–1996 33828 433 773 (820) 4527 (3147) 74 (71) 2795 (2832) 4180 (4267)
Netherlands Cohort Study
Women 62412 131 685 (565) 2901 (1501) 206 (172) 2448 (1028) 1303 (1883)
Men 1986–1992 58279 843 687 (527) 2960 (1453) 155 (164) 2550 (1120) 1045 (1544)
New York State Cohort
Women 21045 130 1144 (854) 6346 (3384) 247 (264) 5998 (3790) 5683 (4100)
Men 1980–1987 27936 392 1171 (865) 6382 (3458) 215 (273) 6025 (3489) 7274 (4764)
Nurses’ Health Study (a)
Women 1980–1986 88307 156 723 (838) 4424 (3629) 104 (92) 5086 (5289) 5255 (5305)
Nurses’ Health Study (b)
Women 1986–1996 68307b 379 764 (637) 4273 (2403) 62 (62) 3531 (2553) 9643 (6133)
Total number 399765 3155
a Only the placebo group of the -Tocopherol, -Carotene Cancer Prevention Study is included in the lung cancer analyses.
b These participants were also included in the Nurses’ Health Study (a).
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these cohort studies), the validity correlation coefficients for
vitamin C may approximate those for -cryptoxanthin. In the
validation studies (31, 33–37, 39), the correlation coefficients
comparing the food frequency questionnaires or closely related
instruments and multiple days of dietary records or 24 h recalls
were between 0.52 and 0.77 for vitamin C. Analyses of fruits
and citrus fruits were only included in the validation studies of
the -Tocopherol, -Carotene Cancer Prevention Study (32),
the Netherlands Cohort Study (36), and Health Professionals
Follow-up Study (41). The correlation coefficients in these
three studies exceeded 0.60 for fruits, citrus fruits, and/or fruit
juices.
Statistical Methods After applying the exclusion criteria used
by each study, we further excluded participants if they reported
energy intakes greater or less than 3 standard deviations from
the study specific loge-transformed mean energy intake, re-
ported a history of cancer (except non-melanoma skin cancer)
at baseline, or had unknown information on smoking habits.
Each study was analyzed using the Cox proportional haz-
ards model (42). Person-years of follow-up were calculated
from the date the baseline questionnaire was returned to the
date of lung cancer diagnosis, date of death, or end of follow-
up, whichever came first. Age at baseline in years and the year
of the baseline questionnaire were included as stratification
variables. The Canadian National Breast Screening Study and
the Netherlands Cohort Study were analyzed as case-cohort
studies (43) using Epicure software (44). In the other studies,
incidence rate ratios were estimated using SAS PROC PHREG
(45).
We analyzed associations with specific carotenoids by
quintiles of intake. Study-specific quintiles were assigned based
on the distributions in the subcohort in the Canadian National
Breast Screening Study and the Netherlands Cohort Study and
based on the distributions in the baseline cohort for the remain-
ing studies. In further analyses, we defined categories using
cutpoints based on identical absolute intakes across studies.
Two-sided 95% confidence intervals (CIs) (95% CIs) and Ps
were calculated. To calculate the P for the test for trend across
categories of intake, participants were assigned the median
value of their category, and this variable was entered as a
continuous term in the regression model.
RRs were adjusted for education, body mass index, alco-
hol consumption, smoking habits, and energy intake (see Table
2 for the categories used). We examined several parameteriza-
tions of smoking habits including controlling for smoking his-
tory as smoking status only, smoking pack-years, a 10-level
categorical variable or as smoking status, years smoked as a
continuous variable for past and current smokers, and amount
smoked among current smokers. Of these, the last model ex-
plained more of the variation in risk and is the one reported
here. Additional models were also adjusted for intakes of vita-
min C, folate, and other carotenoids, and multivitamin use. An
indicator variable for missing responses for measured covari-
ates within a study was created, when needed. We had no
missing data for any nutrients, and for each covariate, data were
missing from 7% of the participants in each study. Because
most of the cohorts included in this pooled analysis did not
calculate carotenoid intakes in their validation studies, we could
not correct our results for measurement error.
We used the random effects model (46) to combine the
study-specific loge RRs that were weighted by the inverse of
their variance. We tested for heterogeneity among studies using
the Q statistic (46, 47). We tested for variation in RRs by sex
and by smoking status using the meta-regression model of
Stram (48). For the analyses stratified by smoking status, iden-
tical quartile cutpoints were used for current, past, and never
smokers within a cohort. We also tested whether associations
differed among adenocarcinomas, small cell carcinomas, and
squamous cell carcinomas using a two degree of freedom
squared Wald test (49). Collectively, these three histological
types represented at least 60% of the cases in each study.
Results
The final pooled data included 3,155 incident lung cancer cases
(1,777 male and 1,378 female) diagnosed among 399,765 par-
Table 2 Pooled relative risks (95% confidence intervals) of lung cancer for quintiles of dietary carotenoids
Carotenoid Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5
P
Test for trend
Test for
between study
heterogeneity
for quintile 5
Test for between
study heterogeneity
due to sex for
quintile 5
-Carotene
Age-adjusted 1.00 0.78 (0.70–0.88) 0.73 (0.65–0.82) 0.70 (0.61–0.80) 0.61 (0.53–0.71) 0.001 0.15 0.06
Multivariatea 1.00 0.91 (0.80–1.05) 0.94 (0.84–1.06) 0.95 (0.84–1.07) 0.93 (0.82–1.06) 0.47 0.39 0.74
-Carotene
Age-adjusted 1.00 0.81 (0.70–0.94) 0.77 (0.67–0.90) 0.69 (0.59–0.80) 0.65 (0.58–0.73) 0.001 0.68 0.73
Multivariatea 1.00 0.97 (0.82–1.16) 1.00 (0.84–1.20) 0.94 (0.82–1.08) 0.98 (0.87–1.11) 0.47 0.85 0.47
-Cryptoxanthin
Age-adjusted 1.00 0.71 (0.64–0.80) 0.59 (0.51–0.69) 0.56 (0.48–0.64) 0.50 (0.43–0.57) 0.001 0.27 0.26
Multivariatea 1.00 0.90 (0.80–1.00) 0.83 (0.71–0.96) 0.86 (0.76–0.97) 0.76 (0.67–0.86) 0.001 0.95 0.60
Lutein/Zeaxanthin
Age-adjusted 1.00 0.86 (0.77–0.96) 0.76 (0.67–0.88) 0.78 (0.69–0.87) 0.74 (0.66–0.83) 0.001 0.57 0.16
Multivariatea 1.00 0.98 (0.87–1.10) 0.92 (0.79–1.06) 0.97 (0.86–1.10) 0.91 (0.81–1.03) 0.15 0.81 0.25
Lycopene
Age-adjusted 1.00 0.78 (0.69–0.87) 0.74 (0.66–0.83) 0.74 (0.66–0.83) 0.77 (0.68–0.88) 0.03 0.25 0.55
Multivariatea 1.00 0.86 (0.75–0.97) 0.85 (0.74–0.99) 0.88 (0.77–1.01) 0.91 (0.78–1.07) 0.42 0.11 0.92
a Adjusted for education (high school graduate, high school graduate, andhigh school graduate), body mass index (23, 23 to25, 25 to30, and30 kg/m2), alcohol
consumption (0, 0 to 5, 5 to 15, 15 to 30, and 30 g/day), energy (continuous), smoking status (current, past, and never smokers), smoking duration for current
smokers (continuous), smoking duration for past smokers (continuous), and amount smoked for current smokers (continuous). Because the -Tocopherol, -Carotene
Cancer Prevention Study only includes current smokers, in this study we adjusted for smoking as smoking duration (continuous) and amount smoked (continuous).
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ticipants who were followed for up to 7–16 years across studies
(Table 1). The follow-up rate for these studies generally ex-
ceeded 90%. Carotenoid intakes varied across the cohorts (Ta-
ble 1). The -Tocopherol, -Carotene Cancer Prevention Study
reported the lowest intakes of each carotenoid, and the New
York State Cohort reported the highest intakes with the one
exception being that lycopene intake was the highest in the
Health Professionals Follow-up Study. Among current smok-
ers, the median Spearman correlation coefficients across studies
between intake of each carotenoid and the number of cigarettes
smoked per day was 0.09 for -carotene, 0.09 for -caro-
tene, 0.14 for -cryptoxanthin, 0.07 for lutein, and 0.03
for lycopene.
In the age-adjusted analyses, intakes of all five carotenoids
were inversely associated with lung cancer risk (P, test for trend
0.03; Table 2). The pooled RR for the highest compared with
the lowest quintile of intake ranged between 0.50 for -cryp-
toxanthin and 0.77 for lycopene. The associations were similar
after adjustment for education, body mass index, alcohol con-
sumption, and energy intake (data not shown) but were atten-
uated after additional adjustment for smoking status (as never
versus past versus current smokers) and duration of smoking
and amount smoked as continuous variables. Only the inverse
association between -cryptoxanthin intake and lung cancer
risk remained monotonic and statistically significant (pooled
RR  0.76; 95% CI, 0.67–0.86; for comparison of the highest
versus lowest quintile). Study-specific RRs for the highest
versus lowest quintile of -cryptoxanthin intake were statisti-
cally significantly inverse in the Nurses’ Health Study (b) and
among men in the New York State Cohort. The RR for the
highest quintile was greater than unity only in the Nurses’
Health Study (a) (RR 1.09; 95% CI, 0.68–1.75). None of the
associations was significantly modified by sex in the multiva-
riate analyses (Table 2). In further analyses, lycopene intake
also was not associated with lung cancer risk when the studies
[-Tocopherol, -Carotene Cancer Prevention Study, Canadian
National Breast Screening Study, Netherlands Cohort Study,
and Nurses’ Health Study (a)] not including tomato sauce
consumption in their food frequency questionnaires were ex-
cluded (data not shown). When cases diagnosed during the first
two or four years of follow-up were excluded from the analyses,
the result for each carotenoid was unchanged (data not shown).
The pooled RR for the highest versus lowest quintile of -cryp-
toxanthin intake was 0.79 (95% CI, 0.66–0.95) among cases
younger than 65 years (n  1411), and 0.75 (95% CI, 0.63–
0.90) among cases 65 years and older (n  1743); the Nurses’
Health Study (a) was excluded from the latter stratum because
only one case was at least 65 years of age at diagnosis.
Because certain foods (e.g., carrots, kale, spinach) are
good sources of several carotenoids (5, 7), intakes of some
carotenoids were highly correlated. For example, Spearman
correlation coefficients between -carotene and -carotene in-
takes ranged from 0.66 to 0.98 across studies. However, cor-
relation coefficients between -cryptoxanthin and the other
carotenoids were 0.4. To determine the independent associ-
ation of each carotenoid with lung cancer risk, all five carote-
noids were simultaneously entered in the analyses. Again, the
intake of -cryptoxanthin was inversely associated with lung
cancer risk (pooled RR  0.77; 95% CI, 0.68–0.88; for com-
parison of the highest versus lowest quintile), whereas intakes
of -carotene, -carotene, lutein/zeaxanthin, and lycopene
were not.
Additional adjustment for vitamin C intake (with or with-
out supplemental intakes), folate intake (with or without sup-
plemental intakes), or multivitamin use did not change appre-
ciably the estimates observed in the multivariate analyses for
any of the carotenoids. For example, the pooled RRs of lung
cancer for participants in the highest compared with the lowest
quintile of -cryptoxanthin intake were 0.80 (95% CI, 0.69–
0.93) after adjustment for dietary vitamin C, 0.75 (95% CI,
0.65–0.86) after adjustment for dietary and supplemental vita-
min C intake, 0.77 (95% CI, 0.67–0.88) after adjustment for
dietary and supplemental folate intake, and 0.76 (95% CI,
0.67–0.86) after adjustment for multivitamin use.
We further analyzed the association between -crypto-
xanthin intake and lung cancer risk using identical categories
defined by absolute intake cutpoints across studies. Compared
with -cryptoxanthin intakes 40 g/day (the amount of
-cryptoxanthin in approximately one-fourth of an orange; Ref.
7), the pooled multivariate RRs of lung cancer were 0.91, 0.78,
0.85, and 0.78 (95% CI, 0.69–0.89; P, test for trend 0.001)
for -cryptoxanthin intakes of 40 to 80 g, 80 to 120 g,
120 to 160 g, and 160 g a day, respectively (Fig. 1).
Study-specific RRs for -cryptoxanthin were statistically sig-
nificant among men in the Netherlands Cohort Study (Fig. 2).
The RR for the 160 g/day category was greater than unity
only in the Nurses’ Health Study (a) (RR  1.02; 95% CI,
0.65–1.61).
We examined associations between carotenoid intakes and
lung cancer risk separately among current (number of lung cancer
cases  1915), past (cases  981), and never smokers (cases 
259; Table 3). The -Tocopherol, -Carotene Cancer Prevention
Study was excluded in the analyses of past and never smokers
because this cohort included only current smokers. There were no
statistically significant differences in the RRs for the highest quar-
tile for any of the carotenoids. However, there was a significant
difference among the three smoking strata for the test for trend for
-cryptoxanthin intake (P, test for between-study heterogeneity
due to smoking status  0.01). A significant trend for -cryptox-
anthin intake was observed only among current smokers. Among
never smokers, there was significant between-study heterogeneity
in the RRs for the highest quartile of -cryptoxanthin intake (P
0.02); study-specific RRs comparing the highest versus lowest
quartile ranged from 0.24 (95% CI, 0.06–0.99) among men in the
New York State Cohort to 3.74 (95% CI, 0.99–14.1) among
women in the Netherlands Cohort Study. There was a suggestion
that -cryptoxanthin intake was inversely associated with the risk
of lung cancer among male never smokers (RR  0.46; 95% CI,
0.22–0.95 comparing the highest versus lowest quartile) but not
female never smokers (RR  1.05; 95% CI, 0.48–2.31; P for
Fig. 1. Pooled multivariate relative risks and 95% confidence intervals for lung
cancer by categories of -cryptoxanthin intake. Relative risks were adjusted for
the same covarietes listed in Table 2. For context, an orange contains about 160
g of -cryptoxanthin (Ref. 7).
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between-study heterogeneity due to sex  0.12). High lycopene
intake was marginally associated with a lower risk of lung cancer
in current smokers (P, test for trend  0.06).
For each carotenoid, there were no statistically significant
differences in the associations for adenocarcinomas (number of
lung cancer cases 956), small cell carcinomas (cases 538),
and squamous cell carcinomas (cases  901; Table 4). The
women in the New York State Cohort were excluded from the
analyses of small cell carcinomas because there were only 14
such carcinomas in this study. The association between -cryp-
toxanthin intake and lung cancer risk was significantly inverse
for all histological types. No associations between intakes of
the other carotenoids and lung cancer risk by histological types
were found.
Fig. 2. Study-specific and pooled multivariate-
adjusted relative risks (RRs) and (95% confidence
intervals) of lung cancer between the highest (160
g/day) and lowest (40 g/day) absolute intake
cutpoint categories for -cryptoxanthin intake. For
context, an orange contains about 160 g of -cryp-
toxanthin; Reference 7. RRs were adjusted for the
same covariates listed in Table 2. The black squares
and horizontal lines correspond to the study-specific
RRs and 95% confidence intervals, respectively, for
the comparison of the highest to lowest categories of
-cryptoxanthin intake. The area of the black squares
reflects the study-specific weight (inverse of the vari-
ance). The diamond represents the pooled RR and
95% confidence interval. The vertical dash line rep-
resents the pooled RR. ATBC, -Tocopherol, -Car-
otene Cancer Prevention study; CNBSS, Canadian
National Breast Screening Study; HPFS, Health Pro-
fessionals Follow-up Study; IWHS, Iowa Women’s
Health Study; NLCS w, Netherlands Cohort Study-
women; NLCS m, Netherlands Cohort Study-men;
NYS w, New York State Cohort-women; NYS m, New
York State Cohort-men; NHS a, Nurses’ Health Study
(a); and NHS b, Nurses’ Health Study (b).
Table 3 Pooled multivariate relative risks (95% confidence intervals) of lung cancer for quartiles of dietary carotenoids by smoking statusa
Carotenoid Quartile 1 Quartile 2 Quartile 3 Quartile 4
P
Test for trend
Test for between
study heterogeneity
for quartile 4
Test for between
study heterogeneity
due to smoking
status for quartile 4
-Carotene
Current smokersb,c 1.00 0.99 (0.87–1.13) 1.08 (0.94–1.23) 0.99 (0.85–1.15) 0.97 0.45
Past smokersb,d,e 1.00 0.90 (0.74–1.11) 0.96 (0.78–1.19) 0.94 (0.72–1.23) 0.44 0.15
Never smokersb,e 1.00 0.77 (0.52–1.13) 0.95 (0.66–1.36) 0.92 (0.64–1.33) 0.82 0.47 0.88
-Carotene
Current smokersb,c 1.00 1.01 (0.85–1.20) 0.98 (0.85–1.13) 0.98 (0.84–1.14) 0.62 0.89
Past smokersb,d,e 1.00 0.88 (0.71–1.07) 0.86 (0.70–1.05) 1.06 (0.86–1.32) 0.61 0.35
Never smokersb,e 1.00 1.11 (0.76–1.62) 0.98 (0.67–1.44) 1.02 (0.70–1.47) 0.73 0.80 0.83
-Cryptoxanthin
Current smokersb,c 1.00 0.84 (0.74–0.96) 0.87 (0.75–1.01) 0.70 (0.60–0.81) 0.001 0.47
Past smokersb,d,e 1.00 0.80 (0.64–1.00) 0.93 (0.73–1.18) 0.84 (0.69–1.03) 0.43 0.45
Never smokersb,e 1.00 0.74 (0.43–1.28) 0.79 (0.45–1.37) 0.77 (0.42–1.42) 0.80 0.02 0.30
Lutein/zeaxanthin
Current smokersb,c 1.00 1.00 (0.87–1.15) 0.95 (0.83–1.09) 0.91 (0.79–1.05) 0.08 0.92
Past smokersb,d,e 1.00 1.05 (0.80–1.38) 0.99 (0.78–1.27) 1.03 (0.84–1.26) 0.69 0.51
Never smokersb,e 1.00 0.87 (0.60–1.28) 0.94 (0.66–1.35) 0.88 (0.61–1.26) 0.75 0.82 0.52
Lycopene
Current smokersb,c 1.00 0.79 (0.68–0.93) 0.85 (0.74–0.98) 0.81 (0.70–0.94) 0.06 0.65
Past smokersb,d,e 1.00 0.89 (0.68–1.15) 0.82 (0.65–1.05) 1.05 (0.86–1.27) 0.76 0.42
Never smokersb,e 1.00 0.80 (0.55–1.17) 0.90 (0.63–1.29) 0.86 (0.60–1.23) 0.29 0.68 0.11
a Number of lung cancer cases were as follows: 1915 current smokers, 981 past smokers, and 259 never smokers.
b Adjusted for education (high school graduate, high school graduate, andhigh school graduate), body mass index (23, 23 to25, 25 to30, and30 kg/m2), alcohol
consumption (0, 0 to 5, 5 to 15, 15 to 30, and 30 g/day), energy (continuous).
c Also adjusted for smoking duration (continuous) and amount smoked (continuous).
d Also adjusted for smoking duration (continuous).
e The -Tocopherol, -Carotene Cancer Prevention Study was excluded because the cohort included only current smokers.
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Discussion
In this pooled analysis of seven cohort studies with a total of
3,155 cases, intakes of -carotene, -carotene, lutein/zeaxan-
thin, and lycopene were not associated with lung cancer risk.
These results do not support some previous suggestions that
high carotenoid intakes are more effective for men than women,
for current smokers compared with past or never smokers, or
for a specific histological type of lung cancer. Intake of -cryp-
toxanthin, however, was inversely associated with lung cancer
risk in categorical analyses using either study-specific quintiles
or identical absolute intake cutpoints. Although there are po-
tentially different sources of misclassification for these two
types of analyses, the pooled multivariate risk of lung cancer
was 22–24% lower in the highest compared with the lowest
category of -cryptoxanthin intake in each analysis. Because
lung cancer is often diagnosed at a late stage (3), dietary
behavior may be altered in individuals with undiagnosed lung
cancer. Our results, however, did not change when cases diag-
nosed during the first 2 or 4 years of follow-up were excluded
from the analyses. Results were also similar after excluding
cases who died within a year of their diagnosis. Furthermore,
the results did not change when only the cases65 years of age
were examined separately.
A comprehensive review by the IARC concluded that the
evidence suggests a lack of cancer preventive activity for sup-
plemental -carotene at high doses (50). However, the evidence
relating usual dietary levels of -carotene or other carotenoids
to the risk of lung cancer was judged to be too limited to be
conclusive. Eleven studies (13–22) have examined the associ-
ation between the intakes of specific carotenoids (-carotene,
-carotene, -cryptoxanthin, lutein, and lycopene) and lung
cancer risk. An analysis from one cohort study included in this
pooled analysis concluded that folate, vitamin C, and -cryp-
toxanthin intakes might be better protective factors against lung
cancer than -carotene, -carotene, lutein/zeaxanthin, and ly-
copene intake (18). Two large United States cohorts also in-
cluded in this pooled analysis reported a significantly lower risk
of lung cancer with higher intakes of -carotene and lycopene
but not with the other carotenoids (17). The -Tocopherol,
-Carotene Cancer Prevention Study from Finland (the placebo
group was included in this pooled analyses) showed an inverse
association between -cryptoxanthin, lycopene, and lutein/
zeaxanthin intakes and lung cancer risk (19). Another cohort
study of Finnish men suggested that dietary -carotene may be
more protective against lung cancer than the other four caro-
tenoids (16). Three case-control studies in the United States
(13, 14, 22) found inverse associations with lung cancer for
dietary -carotene and -carotene; an inverse association was
observed for lutein in two of the studies (13, 14) and crypto-
xanthin in the other study (22). The Canadian National Breast
Screening Study (included in this analysis; Ref. 20) and a small
case-control study (15) found no associations between intakes
of any of the specific carotenoids and lung cancer risk. A recent
case-control study in the United States showed a significantly
lower risk of lung cancer for dietary -carotene, -cryptoxan-
thin, lutein and zeaxanthin, and total carotenoids; however,
after adjustment for total vegetable consumption, the risks for
the specific carotenoids were attenuated and no longer statisti-
cally significant (21).
In addition to the studies examining intakes of specific
carotenoids, two nested case-control studies have shown that
plasma -carotene, -carotene, -cryptoxanthin, and lutein/
zeaxanthin were each inversely associated with lung cancer risk
in analyses that did not control for smoking (51, 52). One of
these studies also presented findings after adjustment for smok-
ing, after which only -cryptoxanthin continued to be inversely
Table 4 Pooled multivariate relative risksa (95% confidence intervals) of lung cancer for quartiles of dietary carotenoids by cell typeb
Carotenoid Quartile 1 Quartile 2 Quartile 3 Quartile 4
P
Test for trend
Test for between
study heterogeneity
for quartile 4
Test for common
effects by cell type
for quartile 4c
-Carotene
Adenocarcinomas 1.00 0.96 (0.82–1.12) 1.14 (0.93–1.38) 0.99 (0.84–1.17) 0.96 0.40
Small cell carcinomasc 1.00 0.91 (0.76–1.10) 1.08 (0.86–1.35) 1.07 (0.88–1.29) 0.53 0.68
Squamous cell carcinomas 1.00 0.83 (0.70–0.98) 0.97 (0.82–1.15) 0.97 (0.80–1.16) 0.86 0.40 0.73
-Carotene
Adenocarcinomas 1.00 0.98 (0.78–1.25) 1.03 (0.88–1.20) 1.04 (0.85–1.27) 0.84 0.19
Small cell carcinomasc 1.00 1.13 (0.85–1.51) 1.03 (0.83–1.27) 1.18 (0.97–1.43) 0.21 0.85
Squamous cell carcinomas 1.00 0.88 (0.73–1.07) 0.96 (0.81–1.14) 1.06 (0.89–1.27) 0.50 0.78 0.66
-Cryptoxanthin
Adenocarcinomas 1.00 0.79 (0.68–0.92) 0.86 (0.72–1.03) 0.80 (0.68–0.93) 0.01 0.77
Small cell carcinomasc 1.00 0.84 (0.69–1.02) 0.74 (0.62–0.90) 0.66 (0.51–0.87) 0.02 0.19
Squamous cell carcinomas 1.00 0.71 (0.60–0.84) 0.76 (0.64–0.90) 0.67 (0.56–0.80) 0.001 0.94 0.24
Lutein/zeaxanthin
Adenocarcinomas 1.00 0.97 (0.78–1.21) 0.99 (0.82–1.19) 0.86 (0.73–1.02) 0.10 0.39
Small cell carcinomasc 1.00 0.96 (0.79–1.15) 1.00 (0.77–1.31) 1.02 (0.85–1.23) 0.71 0.51
Squamous cell carcinomas 1.00 0.94 (0.77–1.15) 0.92 (0.78–1.10) 1.01 (0.85–1.19) 0.96 0.89 0.41
Lycopene
Adenocarcinomas 1.00 0.86 (0.73–1.01) 0.98 (0.83–1.14) 0.93 (0.79–1.09) 0.64 0.96
Small cell carcinomasc 1.00 0.78 (0.65–0.94) 0.89 (0.74–1.07) 0.95 (0.79–1.14) 0.98 0.96
Squamous cell carcinomas 1.00 0.74 (0.62–0.87) 0.80 (0.67–0.95) 0.86 (0.72–1.02) 0.11 0.95 0.64
a Adjusted for education (high school graduate, high school graduate, andhigh school graduate), body mass index (23, 23 to25, 25 to30, and30 kg/m2), alcohol
consumption (0, 0 to 5, 5 to 15, 15 to 30, and 30 g/day), energy (continuous), smoking status (current, past and never smokers), smoking duration for current
smokers (continuous), smoking duration for past smokers (continuous), and amount smoked for current smokers (continuous). Because the -Tocopherol, -Carotene
Cancer Prevention Study only includes current smokers, in this study we adjusted for smoking as smoking duration (continuous) and amount smoked (continuous).
b Number of lung cancer cases were as follows: 956 adenocarcinomas, 538 small cell carcinomas, and 901 squamous cell carcinomas.
c The women in the New York State Cohort were excluded because of too few cases with small cell carcinoma.
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associated with lung cancer risk (51). In a nested case-control
study of Chinese tin miners, serum -cryptoxanthin and -
carotene were each positively associated with lung cancer risk
after adjustment for tobacco use and radon exposure (53).
There is some evidence, albeit limited, relating -crypto-
xanthin intake and the risk of cancers other than lung cancer.
Borderline or statistically significant inverse associations have
been found more often for cancer sites related to smoking
(aerodigestive, esophageal, or cervical cancer; Refs. 54–57)
than for bladder cancer (58) or hormonally related cancers
(breast or prostate cancer; Refs. 59–61).
The majority of epidemiological studies of vegetable and
fruit consumption and lung cancer risk have shown an inverse
relation (1). However, the specific types of vegetables or fruits
as well as the substances that may be responsible for these
associations have remained unclear. We previously found in the
Pooling Project a nonsignificant 12% reduction in lung cancer
risk with high vegetable consumption and a statistically signif-
icant 23% reduction in lung cancer risk with high fruit con-
sumption (62). Among the specific groups of fruits and vege-
tables examined, inverse associations were observed for apples
and pears, for oranges and tangerines, and for orange juice and
grapefruit juice. The inverse association we observed for
-cryptoxanthin complements the finding for fruits because
-cryptoxanthin is mainly derived from oranges, orange juice,
and tangerines (4, 7).
Our study had several strengths. We specified a priori that
we would only include prospective studies that used a validated
food frequency questionnaire to estimate dietary intake. These
inclusion criteria minimized sources of variation because of
study design or study quality. Most of the results in our analyses
were consistent across studies, and the test for between-study
heterogeneity was not statistically significant (P  0.05). We
included only prospective studies because they are less vulner-
able to selection and recall biases that may affect case-control
studies of diet-disease associations. We analyzed the primary
data from these studies rather than conducting a meta-analysis
of the published literature. As a result, we were able to create
identical categories for carotenoid intakes and covariates across
studies, which removes potential sources of heterogeneity that
may occur in a meta-analysis of the published literature.
Our study also had some limitations. Because the associ-
ation between smoking and lung cancer is very strong and
because dietary habits differ between smokers and non-smokers
(1), it is difficult to ensure that all of the potential confounding
by smoking habits has been removed in analyses of dietary
factors in relation to lung cancer risk (63–65). We found in our
study that controlling for smoking status, the number of years
smoked, and the number of cigarettes smoked per day provided
the strongest control of confounding compared with other pa-
rameterizations of smoking history. However, the most remark-
able changes in risks occurred when smoking status was added
to the models. Additional factors that influence lung cancer
risk, such as passive smoking, inhalation patterns, time since
quitting or intensity of smoking among former smokers, the
type of cigarettes smoked, and pipe and cigar smoking habits,
were not generally measured in these cohorts and thus could not
be controlled for in our analysis.
Stram et al. (65) has suggested that differential bias in the
assessment of smoking exposure (usually self-reported) be-
tween smokers with low -carotene intake compared with high
intake may explain much of the observed protective effects of
high -carotene intakes in observational studies. Because in our
study the correlation coefficients between intakes of the spe-
cific carotenoids and the number of cigarettes smoked per day
among current smokers ranged from 0.03 for lycopene to
0.14 for -cryptoxanthin, we cannot exclude some degree of
residual confounding by smoking. But we also observed an
inverse association for -cryptoxanthin among never smokers,
which suggests that the association may not only be because of
confounding by smoking.
Another limitation of our study concerns the assessment of
the intake of the specific carotenoids. We only had a one-time
measure of carotenoid intakes at baseline and were not able to
investigate carotenoid intakes at younger ages or changes in
carotenoid intakes during follow-up. Furthermore, correlation
coefficients between estimated carotenoid intakes and blood
carotenoid concentrations have usually ranged between 0.2 and
0.5, being the highest for -cryptoxanthin (r  0.4–0.5) and
the lowest for lycopene (r  0.3) and lutein (r  0.4; Refs. 40,
66–70). These modest correlations may be explained by errors
in intake estimates due to the dietary questionnaires and nutri-
tional databases (51) or by variation among individuals in
carotenoid bioavailability (40). Furthermore, a single blood
carotenoid measure does not perfectly reflect long-term intake
(71). A human experimental trial, however, found that plasma
-carotene, -carotene, -cryptoxanthin, lutein, and lycopene
responded well to moderate alterations in diet within a short
time, although the magnitude of the response may be related to
the baseline carotenoid concentration (72).
The bioavailability of carotenoids can vary substantially
depending on the cooking method or the presence of other
nutrients (73, 74). It is especially difficult to assess the effect of
lycopene because many food questionnaires do not include all
relevant foods in this respect. Previous studies have shown that
lycopene is more bioavailable in cooked than in raw products
(73). In our data, four of the cohort studies did not ask about
tomato sauce consumption in their food frequency question-
naires. However, no association was found between high intake
of lycopene and lung cancer risk regardless of whether these
four studies were included in the analysis. Furthermore, be-
cause fruits and vegetables contain many compounds that may
decrease cancer risk (75), we also adjusted for vitamin C, folate,
and other carotenoid intakes and for multivitamin use in the
analyses of each carotenoid. Although the associations between
specific carotenoids and lung cancer risk did not change sub-
stantially, it is possible that other substances in fruits and
vegetables, particularly citrus fruit, are primarily responsible
for the inverse associations observed for -cryptoxanthin.
The findings from this combined analysis of several large
prospective studies do not support any benefit of higher intake
of -carotene from dietary sources in the prevention of lung
cancer, nor do they suggest that higher -carotene intake in the
context of normal diets increases lung cancer risk, as was
observed in two of the trials of -carotene supplements (8, 9).
Our results also suggest that high -cryptoxanthin intake may
decrease the risk of lung cancer, but whether -cryptoxanthin
or other bioactive compounds present in fruits are responsible
for this association is unclear and deserves further evaluation.
In addition, because smoking is the main cause of lung cancer,
we cannot rule out the possibility that our results are attribut-
able to residual confounding by smoking. The most effective
actions against lung cancer continue to be smoking prevention
and cessation.
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